Education
About Us
Working with TipRanks
Follow Us
Rani Therapeutics Holdings (RANI)
NASDAQ:RANI
RANI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.39 - $3.75
Previous CloseN/A
Volume228.85K
Average Volume (3M)3.30M
Market Cap
$35.93M
Enterprise Value$26.10M
Total Cash (Recent Filing)$15.85M
Total Debt (Recent Filing)$25.67M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Nov 12, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding47,898,228
10 Day Avg. Volume693,309
30 Day Avg. Volume3,297,759
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue25.39
Enterprise Value/Gross Profit51.48
Enterprise Value/Ebitda-0.53
Forecast
1Y Price Target
$7.00Price Target Upside1220.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical TrialsRani's partner ProGen reported positive Phase I study results of PG-102, demonstrating a favorable tolerability profile and quick onset of the weight loss effect.
PartnershipsRani entered into a research agreement with Chugai Pharmaceutical Co., indicating a significant collaboration.
Product DevelopmentRani has demonstrated successful delivery of semaglutide via RaniPill with comparable bioavailability, weight loss, and PK, which could lead to a nearer term path to revenue in markets where semaglutide is coming off patent.
Bears Say
Financial PerformanceRani Therapeutics reported 1Q25 results with a net loss of ($12.7M) and ended the period with $15.9M in cash, indicating the company will require additional capital in the near term.
RisksRisks include, but are not limited to: negative Phase 2 data; negative clinical readouts with other candidates; failure to achieve approvals for key pipeline projects; possible partnership risk; slower-than-projected market uptake.
Rani Therapeutics Holdings News
RANI FAQ
What was Rani Therapeutics Holdings’s price range in the past 12 months?
Rani Therapeutics Holdings lowest stock price was $0.39 and its highest was $3.75 in the past 12 months.
What is Rani Therapeutics Holdings’s market cap?
Rani Therapeutics Holdings’s market cap is $35.93M.
When is Rani Therapeutics Holdings’s upcoming earnings report date?
Rani Therapeutics Holdings’s upcoming earnings report date is Nov 12, 2025 which is in 90 days.
How were Rani Therapeutics Holdings’s earnings last quarter?
Rani Therapeutics Holdings released its earnings results on Aug 07, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.285 by $0.105.
Is Rani Therapeutics Holdings overvalued?
According to Wall Street analysts Rani Therapeutics Holdings’s price is currently Undervalued.
Does Rani Therapeutics Holdings pay dividends?
Rani Therapeutics Holdings does not currently pay dividends.
What is Rani Therapeutics Holdings’s EPS estimate?
Rani Therapeutics Holdings’s EPS estimate is -0.17.
How many shares outstanding does Rani Therapeutics Holdings have?
Rani Therapeutics Holdings has 47,898,228 shares outstanding.
What happened to Rani Therapeutics Holdings’s price movement after its last earnings report?
Rani Therapeutics Holdings reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.285. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Rani Therapeutics Holdings?
Currently, no hedge funds are holding shares in RANI
Rani Therapeutics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (1220.75% Upside)
$7.00 (1220.75% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.61%
12-Months-Change
Fundamentals
Return on Equity
-1372.59%
Trailing 12-Months
Asset Growth
-61.35%
Trailing 12-Months
Company Description
Rani Therapeutics Holdings
Rani Therapeutics Holdings (RANI) is a healthcare company focused on developing innovative oral biologics utilizing its proprietary RaniPill technology. The company operates within the biotechnology and pharmaceutical sectors, offering a unique solution for the oral delivery of biologics, which are traditionally administered via injection. Rani's core product, the RaniPill capsule, is designed to deliver large-molecule drugs through the gastrointestinal tract, thereby improving patient compliance and expanding the potential market for biologic therapies.
RANI Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in Rani's technology and pipeline, particularly in the obesity treatment market, supported by strategic partnerships and successful preclinical data. However, financial challenges remain, as evidenced by decreased cash reserves and a substantial net loss for the year.View all RANI earnings summariesRANI Stock 12 Month Forecast
Average Price Target
$7.00
▲(1220.75% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Adverum Biotechnologies
―
IGM Biosciences
―
Adagene
―
TScan Therapeutics
―
Ownership Overview
24.83% Insiders
2.53% Mutual Funds
0.13% Other Institutional Investors
70.39% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---